BROWSE·page 414 of 651

Browse EX-10 agreements

7,802 total material contract exhibits.


EXHIBIT 10.1

Sadot Group Inc.

WRITTEN OPTION AGREEMENT

FOR THE ACQUISITION OF A REAL ESTATE PORTFOLIO

 

Between

 

ANAT ATTIA

Individually and as Sole Member of Each Property LLC

(“Grantor”)

 

and

 

SADOT GROUP INC.

a Nevada corporation

(“Optionee”)

 

Dated: June 10, 2026

 

Portfolio Summary

7 Properties | 147 Units | $56,000,000 Existing Loans | $125,500,000 Total Value

Portfolio Equity: $69,500,000 | Option Fee: $1,042,500 | Option Period: 6 Months

 

 

 

RECITALS

 

WHEREAS, Grantor is the sole member and manager of each of the limited liability companies listed in Schedule 1 hereto (the “Property LLCs”), each of which owns or controls one or more real property assets located in the State of California (collectively, the “Portfolio Properties”);

EX-10.1·8-K·CIK 1701756·ACC 0001731122-26-000850·Filed Jun 12, 2026, 17:00 ET

EXHIBIT 10.2

Sadot Group Inc.

AMENDMENT NO. 1 TO

WRITTEN OPTION AGREEMENT

FOR THE ACQUISITION OF A REAL ESTATE PORTFOLIO

 

Between

ANAT ATTIA

Individually and as Sole Member of Each Property LLC

(“Grantor”)

 

and

 

SADOT GROUP INC.

a Nevada corporation

(“Optionee”)

 

Dated: June 10, 2026

 

THIS AMENDMENT NO. 1 TO WRITTEN OPTION AGREEMENT (this “Amendment”) is entered into as of June 10, 2026 (the “Amendment Date”), by and between ANAT ATTIA, individually and as sole member of each of the Property LLCs identified in the Agreement (as defined below) (“Grantor”), and SADOT GROUP INC., a Nevada corporation listed on the Nasdaq Capital Market under ticker symbol “SDOT” (“Optionee”).

 

RECITALS

 

WHEREAS, Grantor and Optionee entered into that certain Written Option Agreement for the Acquisition of a Real Estate Portfolio (the “Agreement”), bearing the date of June 10, 2026, covering a portfolio of seven (7) California real estate projects comprising in aggregate 147 residential units, as more particularly described therein;

EX-10.2·8-K·CIK 1701756·ACC 0001731122-26-000850·Filed Jun 12, 2026, 17:00 ET

EXHIBIT 10.1

VisionWave Holdings, Inc.

VisionWave Holdings, Inc.

300 Delaware Ave., Suite 210#301

Wilmington, Delaware 19801

 

June 11, 2026

 

VIA EMAIL

 

Danny Rittman

 

Re: Amendment No. 1 to Employment Agreement dated August 6, 2025

 

Dear Danny:

 

This letter agreement (this “Amendment”) is entered into as of June 11, 2026, by and between VisionWave Holdings, Inc., a Delaware corporation (the “Company”), and Danny Rittman (“Executive”).

 

RECITALS

 

WHEREAS, the Company and Executive are parties to that certain Employment Agreement dated August 6, 2025 (the “Original Agreement”); and

 

WHEREAS, the parties desire to amend the Original Agreement on the terms and conditions set forth herein;

 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

EX-10.1·8-K·CIK 2038439·ACC 0001731122-26-000849·Filed Jun 12, 2026, 17:00 ET

TICKETPLUS LTD.

RESTRICTED SHARE AGREEMENT

 

THIS RESTRICTED SHARE AGREEMENT (this “Agreement”) is dated as of [__], 2026, between Ticketplus Ltd., a Cayman Islands exempted company (the “Company”), and [__] (“Recipient”).

 

BACKGROUND

 

The Board of Directors of the Company has determined that Recipient is eligible to receive certain ordinary shares of a par value of US$0.0001 each in the Company (the “Ordinary Shares”) as provided herein. The Ordinary Shares issued pursuant to this Agreement are subject to the terms and conditions set forth in this Agreement.

AGREEMENT

 

NOW, THEREFORE, it is agreed between the parties as follows:

 

SECTION 1.  ISSUANCE OF SHARES; VESTING; CONTINUOUS SERVICE.

 

(i) Pursuant to the terms of this Agreement, the Company agrees to grant and issue to the Recipient on the date hereof [__] Ordinary Shares (the “Shares”). It is acknowledged and agreed that the aggregate fair market value of the Shares issued hereunder as of the date of this Agreement is not more than US$[__] (US$[__] per share).

EX-10.12·F-1/A·CIK 2104296·ACC 0001213900-26-068348·Filed Jun 12, 2026, 16:59 ET

ENGLISH TRANSLATION OF

EMPLOYMENT AGREEMENT

 

In Santiago, Chile, on [__], by and among Ticketplus Ltd., a Cayman Islands exempted company (the “Company”), and Ticketplus SpA, taxpayer identification number (R.U.T.) [__], legally represented by [__], both domiciled at Alonso de Córdova N°5320, 16th floor, Las Condes District, Metropolitan Region, with electronic address legal@ticketplus.com (the “Employer”), as one party; and on the other party, [__], of Chilean nationality, national identity card number [__], born on [__], domiciled at [__], with electronic address [__], (the “Executive”), have agreed upon the following employment agreement, hereinafter the “Agreement”:

 

RECITALS

EX-10.7·F-1/A·CIK 2104296·ACC 0001213900-26-068348·Filed Jun 12, 2026, 16:59 ET

SECURITIES SUBSCRIPTION AGREEMENT, DATED MAY 19, 2026

Thunder Bridge Capital Partners V, Ltd.

Thunder Bridge Capital Partners V, Ltd.

9912 Georgetown Pike, Suite D203

Great Falls, Virginia 22066

 

May 19, 2026

 

TBCP V, LLC

9912 Georgetown Pike, Suite D203

Great Falls, Virginia 22066

 

RE: Securities Subscription Agreement

 

Ladies and Gentlemen:

 

We are pleased to accept the offer TBCP V, LLC (the “Subscriber” or “you”) has made to purchase 7,503,750 Class B ordinary shares (the “Shares”), $0.0001 par value per share (the “Class B Shares”), up to 978,750 Shares of which are subject to complete or partial forfeiture by you if the underwriters of the initial public offering (“IPO”) of Thunder Bridge Capital Partners V, Ltd., a Cayman Islands exempted company (the “Company”), do not fully exercise their over-allotment option (the “Over-allotment Option”). For the purposes of this Agreement, references to “Ordinary Shares” are to, collectively, the Class B Shares and the Company’s Class A ordinary shares, $0.0001 par value per share (the “Class A Shares”). Pursuant to the Company’s memorandum and articles of association, as amended to the date hereof (the “Article

EX-10.1·S-1·CIK 2140030·ACC 0001213900-26-068341·Filed Jun 12, 2026, 16:57 ET

EX-10.1 REVOLVING CREDIT AGREEMENT

BioRestorative Therapies, Inc.

Execution Version

 

REVOLVING LOAN AGREEMENT`

 

This Revolving Loan Agreement (this “Agreement”) is dated as of June 10, 2026, between BioRestorative Therapies, Inc. (the “Borrower”), and the lender identified on the signature page hereto (including its successors and assigns, the “Lender”).

 

WHEREAS, Borrower wishes to obtain Loans from time to time from Lender in an aggregate principal amount at any one time outstanding not to exceed the Maximum Outstanding Amount, and Lender wishes to provide such Loans, all on the terms and subject to the conditions hereinafter set forth;

 

NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower and Lender agree as follows:

ARTICLE I DEFINITIONS

 

Section 1.01. Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings set forth in this Agreement.

 

“$” means United States Dollars.

EX-10.1·8-K·CIK 1505497·ACC 0001021771-26-000091·Filed Jun 12, 2026, 16:56 ET

EX-10.2 PROMISSORY NOTE

BioRestorative Therapies, Inc.

Execution Version

 

APPENDIX A TO REVOLVING LOAN AGREEMENT

Form of Revolving Promissory Note

THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

Original Issue Date:

[Closing Date]

Maximum Principal Amount:

$1,000,000 (the Maximum Outstanding Amount)

Final Maturity Date:

First anniversary of the Closing Date

Interest Rate:

12% per annum

Default Rate:

16% per annum

 

BIORESTORATIVE THERAPIES, INC.

REVOLVING PROMISSORY NOTE

EX-10.2·8-K·CIK 1505497·ACC 0001021771-26-000091·Filed Jun 12, 2026, 16:56 ET

EX-10.1

I-ON Digital Corp.

I-ON Digital Corp.

 

2026 Equity Incentive Plan

Date of Approval: June 8, 2026

 

1.

General.

 

(a) Name of Plan. The name of this Plan is the “I-ON Digital Corp 2026 Equity Incentive Plan.”

 

(b) Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive Awards.

 

(c) Available Awards. The Plan provides for the grant of the following types of Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards.

 

(d) Purpose. The Plan, through the granting of Awards, is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.

 

2.

Administration.

EX-10.1·8-K·CIK 1580490·ACC 0001493152-26-028491·Filed Jun 12, 2026, 16:53 ET

EX-10.1

Neuraxis, INC

Neuraxis, Inc.

2022 Omnibus Securities and Incentive Plan (As Amended As of June 11, 2026)

 

Table of Contents

 

 

 

Page

 

 

 

 

ARTICLE I

PURPOSE

1

 

 

 

ARTICLE II

DEFINITIONS

1

 

 

 

ARTICLE III

EFFECTIVE DATE OF PLAN

6

 

 

 

ARTICLE IV

ADMINISTRATION

6

 

Section 4.1

Administration

6

 

Section 4.2

Powers

6

 

Section 4.3

Additional Powers

6

 

Section 4.4

Delegation

6

 

Section 4.5

Power and Authority of the Board

6

 

 

 

 

ARTICLE V

Stock SUBJECT TO PLAN AND LIMITATIONS THEREON

7

 

Section 5.1

Stock Grant and Award Limits

7

 

Section 5.2

Prior Stock Plan

7

 

Section 5.3

Common Stock Offered

7

 

 

 

 

ARTICLE VI

ELIGIBILITY FOR AWARDS

7

 

 

 

ARTICLE VII

OPTIONS

7

 

Section 7.1

Option Period

7

 

Section 7.2

Limitations on Exercise of Option

7

 

Section 7.3

Special Limitations on Incentive Stock Options

8

 

Section 7.4

Option Agreement

8

 

Section 7.5

Option Price and Payment

8

 

Section 7.6

Stockholder Rights and Privileges

9

 

Section 7.7

EX-10.1·8-K·CIK 1933567·ACC 0001493152-26-028489·Filed Jun 12, 2026, 16:50 ET

EX-10.2

Neuraxis, INC

Employee Stock Purchase Plan (“ESPP”)

 

NEURAXIS, INC.

 

2025 EMPLOYEE STOCK PURCHASE PLAN

 

Compensation Committee and Board of Directors Approval: July 1, 2025 (amendment approved by the Compensation Committee and Board of Directors on April 9, 2026)

APPROVED BY THE STOCKHOLDERS: June 10, 2026

EFFECTIVE DATE: July 1, 2025

 

1.

General; Purpose.

 

(a) The Plan provides a means by which Eligible Employees of the Company may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan.

EX-10.2·8-K·CIK 1933567·ACC 0001493152-26-028489·Filed Jun 12, 2026, 16:50 ET

EXHIBIT 10.1

Inventiva S.A.

AMENDMENT AGREEMENT

 

THIS AMENDMENT AGREEMENT is made on 12 June 2026

 

BETWEEN:

 

1.

INVENTIVA, a limited company (société anonyme) incorporated under the laws of France, having its registered office at 50, rue de Dijon – 21121 DAIX, France, registered under single identification number 537 530 255 RCS Dijon;

 

(hereinafter referred to as the "Issuer" or the "Company")

 

ON THE FIRST PART

 

AND

 

2.

KREOS CAPITAL VIII (UK) LTD, a company incorporated in England and Wales under registration number 16637390 whose registered office is at 5 Churchill Place, 10th Floor, London, United Kingdom, E14 5HU,

 

3.

Claret European Specialty Lending Company IV, S.à r.l. a limited company (société à responsabilité limitée) incorporated under the laws of Luxembourg, having its registered office at 412F, route d'Esch, L-1471 Luxembourg, registered under identification number B291023,

 

4.

EX-10.1·6-K·CIK 1756594·ACC 0001104659-26-073545·Filed Jun 12, 2026, 16:45 ET